Business
Bruker Appoints Laura Francis to its Board of Directors
BILLERICA, Mass.--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its
About this update from Bruker Corporation
[{"type":"text","content":" BILLERICA, Mass.--(BUSINESS WIRE)--\nBruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker’s Audit Committee as a financial expert after Bruker’s annual shareholder meeting at the end of May 2025.\n\nLaura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (Nasdaq: SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with public and private life science companies, including Bruker Corporation, as well as Auxogyn, now part of Progyny (Nasdaq: PGNY), and Promega Corporation. Earlier in her career, she was an Engagement Manager with McKinsey & Company and Audit Manager with Coopers & Lybrand, now PricewaterhouseCoopers.\n\nMs. Francis previously also was a board member of Shockwave Medical, Inc. (Nasdaq: SWAV), a medical device company, where she served as audit committee chair and compensation committee member. Ms. Francis earned a B.B.A. in Accounting and Finance from the University of Wisconsin and an M.B.A. from Stanford University. She is a Certified Public Accountant (inactive) in the State of California.\n\n“I am honored to join the Board of Directors at Bruker Corporation, a company I deeply respect and had the privilege of serving as CFO earlier in my career,” said Ms. Francis. “I look forward to contributing to Bruker’s continued innovation and growth in the life sciences and diagnostics industries.”\n\nFrank H. Laukien, chairman, president and CEO of Bruker Corporation stated: “On behalf of our board and entire company, we warmly welcome Laura to our board of directors. Her experience as a public company medtech CEO, along with her CFO and COO experience in both the medtech and life science tools industries is going to be very valuable in guiding Bruker’s profitable growth and strategy execution. Laura is an impressive and accomplished leader, and she is a wonderful addition to our board.”\n\nAbout Bruker Corporation – Leader of the Post-Genomic Era\n\nBruker is enabling scientists and engineers to make breakth...